PXD041909
PXD041909 is an original dataset announced via ProteomeXchange.
Dataset Summary
Title | Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib |
Description | Background: Acute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study, we hypothesized that Ruxo's mode of action in this condition is reflected by changes in the peripheral blood proteome. Methods: This study included 11 COVID-19 patients, who were treated our center's Intensive Care Unit (ICU). All patients received standard-of-care treatment and n=8 patients with ARDS received Ruxo in addition. Blood samples were collected before (day 0) and on days 1, 6, and 10 of Ruxo treatment or, respectively, ICU admission. Serum proteomes were analyzed by mass spectrometry (MS) and cytometric bead array. Results: Linear modelling of MS data yielded 27 significantly differentially regulated proteins on day 1, 69 on day 6 and 72 on day 10. Only five factors (IGLV10-54, PSMB1, PGLYRP1, APOA5, WARS1) were regulated both concordantly and significantly over time. Overrepresentation analysis revealed biological processes involving T-cells only on day 1, while a humoral immune response and complement activation were detected at day 6 and day 10. Pathway enrichment analysis identified the NRF2-pathway early under Ruxo treatment and Network map of SARS-COV-2 signaling and Statin inhibition of cholesterol production at later time points. Conclusions: Our results indicate that the mechanism of action of Ruxo in COVID-19-ARDS can be related to both known effects of this drug as a modulator of T-cells and the SARS-CoV-2-infection. |
HostingRepository | MassIVE |
AnnounceDate | 2023-05-03 |
AnnouncementXML | Submission_2023-05-03_05:30:12.500.xml |
DigitalObjectIdentifier | |
ReviewLevel | Non peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Johannes Graumann |
SpeciesList | scientific name: Homo sapiens; common name: human; NCBI TaxID: 9606; |
ModificationList | Oxidation; Acetyl; Carbamidomethyl |
Instrument | Q Exactive Plus; Q Exactive HF |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
---|---|---|---|
0 | 2023-05-01 10:06:54 | ID requested | |
⏵ 1 | 2023-05-03 05:30:12 | announced |
Publication List
no publication |
Keyword List
submitter keyword: SARS-CoV-2, COVID-19, Ruxolitinib, acute respiratory distress syndrome, proteomics |
Contact List
Elisabeth K.M. Mack | |
---|---|
contact affiliation | Philipps-University Marburg and University Hospital Giessen and Marburg, Campus Marburg |
contact email | elisabeth.mack@staff.uni-marburg.de |
lab head | |
Chrysanthi Skevaki | |
contact affiliation | Institute of Laboratory Medicine, Philipps-University Marburg |
contact email | Chrysanthi.Skevaki@uk-gm.de |
lab head | |
Johannes Graumann | |
contact affiliation | Philipps-University Marburg |
contact email | johannes.graumann@uni-marburg.de |
dataset submitter |
Full Dataset Link List
MassIVE dataset URI |
Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://massive.ucsd.edu/MSV000091706/ |